| |
|
|
|
Anavex Life Sciences Corp.  
|
|
2.54 -0.21 (-0.08%) |
10-22 16:00 |
|
Open: |
2.68 |
Pre close: |
2.75 |
Target:
|
3.31 
|
|
High: |
2.68 |
Low: |
2.4712 |
Resistance:
|
2.84
3.21
|
|
Volume: |
429,339 |
Market Cap: |
115M |
Support:
|
2.23
1.86
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
2.55
|
MACD |
MACD(12,26):
|
-0.02  |
|
MA(20): |
2.60 |
Signal(12,26,9): |
-0.03 |
|
MA(100): |
2.96 |
Stochastic Oscillator |
%K(14,3):
|
34.24 |
|
MA(250): |
2.97 |
%D(3): |
28.83 |
|
Average Volume(K) |
3-Month: |
28633
|
52-Week |
High:
|
4.69 |
|
10-Days: |
42233 |
Low: |
1.85 |
|
RSI |
RSI(14):
|
48.73 |
Change(%): |
-46.1 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.380 |
Return on Equity (ttm) |
-71.5 |
Shares Out. (M) |
45.43 |
|
EPS Est. Current Year |
-0.370 |
Return on Assets (ttm) |
-65.1 |
Shares Float (M) |
35.29 |
|
EPS Est. Next Year |
-0.450 |
PEG Ratio |
0.00 |
% Held by Insiders |
22.70 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
19.80 |
|
Forward EPS |
-0.480 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
5766 |
|
Book Value (p.s.) |
4.760 |
EBITDA (p.s.) |
-0.090 |
P/E |
-6.68 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
0.53 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-10.72 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-4.59 |
P/CF |
-10.76 |
|
|
|
|
|
|
